A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 2, 2012, Pages 100-107

  Reeves, Emer P ^a   Bergin, David A ^a   Fitzgerald, Sean ^a   Hayes, Elaine ^a   Keenan, Joanne ^b   Henry, Michael ^b   Meleady, Paula ^b   Vega Carrascal, Isabel ^a   Murray, Michelle A ^a   Low, Teck Boon ^a   McCarthy, Cormac ^a   O'Brien, Emmet ^a   Clynes, Martin ^b   Gunaratnam, Cedric ^a   McElvaney, Noel G ^a  

^a BEAUMONT HOSPITAL   (Ireland)

^b DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Alpha 1 antitrypsin; CD16b; Cystic fibrosis; Infection; Inflammation; Pulmonary exacerbation

Indexed keywords

ALPHA 1 ANTITRYPSIN; CD16 ANTIGEN; CIPROFLOXACIN; COLISTIN; FLUCLOXACILLIN; INTERLEUKIN 8; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CELL MEMBRANE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; LUNG FIBROSIS; NEUTROPHIL; PROTEIN BLOOD LEVEL;

ADULT; ALPHA 1-ANTITRYPSIN; ANTIGENS, CD; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES, NEURONAL; CYSTIC FIBROSIS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FETAL PROTEINS; HUMANS; MALE; NEUTROPHILS; PROTEOMICS; YOUNG ADULT;

EID: 84858291535     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2011.09.010     Document Type: Article

References (44)

1. Davis P.B. Cystic fibrosis since 1938. Am J Respir Crit Care Med Mar 1 2006, 173(5):475-482.
2. Boucher R.C. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med Jun 2007, 13(6):231-240.
3. Hassett D.J., Korfhagen T.R., Irvin R.T., Schurr M.J., Sauer K., Lau G.W., et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets Feb 2010, 14(2):117-130.
4. Kahl B.C. Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease. Int J Med Microbiol Dec 2010, 300(8):514-519.
5. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G., Muhlebach M.S., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med May 1 2008, 177(9):995-1001.
6. Worlitzsch D., Rintelen C., Bohm K., Wollschlager B., Merkel N., Borneff-Lipp M., et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect May 2009, 15(5):454-460.
7. Downey D.G., Brockbank S., Martin S.L., Ennis M., Elborn J.S. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol Aug 2007, 42(8):729-735.
8. Tabary O., Zahm J.M., Hinnrasky J., Couetil J.P., Cornillet P., Guenounou M., et al. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol Sep 1998, 153(3):921-930.
9. Muhlebach M.S., Noah T.L. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med Apr 1 2002, 165(7):911-915.
10. Stoltz D.A., Meyerholz D.K., Pezzulo A.A., Ramachandran S., Rogan M.P., Davis G.J., et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med Apr 28 2010, 2(29):29ra31.
11. Heinzl B., Eber E., Oberwaldner B., Haas G., Zach M.S. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol Jan 2002, 33(1):32-37.
12. Ratjen F., Doring G., Nikolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet Sep 22 2001, 358(9286):983-984.
13. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med Sep 8 1994, 331(10):637-642.
14. Rabin H.R., Butler S.M., Wohl M.E., Geller D.E., Colin A.A., Schidlow D.V., et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol May 2004, 37(5):400-406.
15. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med Jan 7 1999, 340(1):23-30.
16. Rosenfeld M., Emerson J., Williams-Warren J., Pepe M., Smith A., Montgomery A.B., et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr Sep 2001, 139(3):359-365.
17. Dakin C., Henry R.L., Field P., Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol Jun 2001, 31(6):436-442.
18. Bilton D., Canny G., Conway S., Dumcius S., Hjelte L., Proesmans M., et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros Jun 2011, 10(Suppl. 2):S79-S81.
19. Jensen P.O., Moser C., Kharazmi A., Presler T., Koch C., Hoiby N. Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia. J Cyst Fibros Aug 2006, 5(3):145-151.
20. Roderfeld M., Rath T., Schulz R., Seeger W., Tschuschner A., Graf J., et al. Serum matrix metalloproteinases in adult CF patients: relation to pulmonary exacerbation. J Cyst Fibros Sep 2009, 8(5):338-347.
21. Eickmeier O., Huebner M., Herrmann E., Zissler U., Rosewich M., Baer P.C., et al. Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function. Cytokine May 2010, 50(2):152-157.
22. Sagel S.D., Sontag M.K., Wagener J.S., Kapsner R.K., Osberg I., Accurso F.J. Induced sputum inflammatory measures correlate with lung function in children with cystic fibrosis. J Pediatr Dec 2002, 141(6):811-817.
23. Sloane A.J., Lindner R.A., Prasad S.S., Sebastian L.T., Pedersen S.K., Robinson M., et al. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects. Am J Respir Crit Care Med Dec 1 2005, 172(11):1416-1426.
24. Martin S.L., Moffitt K.L., McDowell A., Greenan C., Bright-Thomas R.J., Jones A.M., et al. Association of airway cathepsin B and S with inflammation in cystic fibrosis. Pediatr Pulmonol Sep 2010, 45(9):860-868.
25. Bergin D.A., Reeves E.P., Meleady P., Henry M., McElvaney O.J., Carroll T.P., et al. alpha-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest Dec 1 2010, 120(12):4236-4250.
26. Bergin D.A., Reeves E.P., Fitzgerald S., Vega-Carrascal I., Hayes E., Keenan J., Clynes M., Low T.B., O' Neill S.J., McElvaney N.G. Neutrophil derived CD16B: alpha-1 antitrypsin complex; a novel biomarker of inflammation in cystic fibrosis. Am J Respir Crit Care Med 2011, 183:A5739.
27. Greene C.M., Low T.B., O'Neill S.J., McElvaney N.G. Anti-proline-glycine-proline or antielastin autoantibodies are not evident in chronic inflammatory lung disease. Am J Respir Crit Care Med Jan 1 2010, 181(1):31-35.
28. Wilmott R.W., Amin R.S., Colin A.A., DeVault A., Dozor A.J., Eigen H., et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med Jun 1996, 153(6 Pt 1):1914-1917.
29. Lovell M.A., Lynn B.C., Xiong S., Quinn J.F., Kaye J., Markesbery W.R. An aberrant protein complex in CSF as a biomarker of Alzheimer disease. Neurology Jun 3 2008, 70(23):2212-2218.
30. Shao M.X., Ueki I.F., Nadel J.A. Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A Sep 30 2003, 100(20):11618-11623.
31. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr Aug 2007, 151(2). 134-9, 9 e1.
32. Schulz B.L., Sloane A.J., Robinson L.J., Prasad S.S., Lindner R.A., Robinson M., et al. Glycosylation of sputum mucins is altered in cystic fibrosis patients. Glycobiology Jul 2007, 17(7):698-712.
33. Ordonez C.L., Henig N.R., Mayer-Hamblett N., Accurso F.J., Burns J.L., Chmiel J.F., et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med Dec 15 2003, 168(12):1471-1475.
34. Foell D., Seeliger S., Vogl T., Koch H.G., Maschek H., Harms E., et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax Jul 2003, 58(7):613-617.
35. Gray R.D., Imrie M., Boyd A.C., Porteous D., Innes J.A., Greening A.P. Sputum and serum calprotectin are useful biomarkers during CF exacerbation. J Cyst Fibros May 2010, 9(3):193-198.
36. Brockbank S., Downey D., Elborn J.S., Ennis M. Effect of cystic fibrosis exacerbations on neutrophil function. Int Immunopharmacol Mar 2005, 5(3):601-608.
37. Niggemann B., Stiller T., Magdorf K., Wahn U. Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection. Mediators Inflamm 1995, 4(4):282-288.
38. Forehand J.R., Pabst M.J., Phillips W.A., Johnston R.B. Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst. Role of intracellular free calcium. J Clin Invest Jan 1989, 83(1):74-83.
39. Hallett M.B., Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol Today Jun 1995, 16(6):264-268.
40. Mukherjee G., Quinn M.T., Linner J.G., Jesaitis A.J. Remodeling of the plasma membrane after stimulation of neutrophils with f-Met-Leu-Phe and dihydrocytochalasin B: identification of membrane subdomains containing NADPH oxidase activity. J Leukoc Biol Jun 1994, 55(6):685-694.
41. Pedersen S.S., Kharazmi A., Espersen F., Hoiby N. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response. Infect Immun Oct 1990, 58(10):3363-3368.
42. Taggart C., Coakley R.J., Greally P., Canny G., O'Neill S.J., McElvaney N.G. Increased elastase release by CF neutrophils is mediated by tumor necrosis factor-alpha and interleukin-8. Am J Physiol Lung Cell Mol Physiol Jan 2000, 278(1):L33-L41.
43. Fleit H.B., Kobasiuk C.D., Daly C., Furie R., Levy P.C., Webster R.O. A soluble form of Fc gamma RIII is present in human serum and other body fluids and is elevated at sites of inflammation. Blood May 15 1992, 79(10):2721-2728.
44. Hommes D.W., Meenan J., de Haas M., ten Kate F.J., von dem Borne A.E., Tytgat G.N., et al. Soluble Fc gamma receptor III (CD 16) and eicosanoid concentrations in gut lavage fluid from patients with inflammatory bowel disease: reflection of mucosal inflammation. Gut Apr 1996, 38(4):564-567.